Lineage Cell Therapeutics, Inc. (LCTX)
NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 209.27M |
| Enterprise value | 176.73M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 21.43 |
| Price/book (mrq) | 3.30 |
| Enterprise value/revenue | 19.76 |
| Enterprise value/EBITDA | -7.35 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.33 |
| 52-week change 3 | -18.38% |
| S&P500 52-week change 3 | 21.08% |
| 52-week high 3 | 1.6100 |
| 52-week low 3 | 0.8400 |
| 50-day moving average 3 | 1.2210 |
| 200-day moving average 3 | 1.2007 |
Share statistics
| Avg vol (3-month) 3 | 965.6k |
| Avg vol (10-day) 3 | 881.61k |
| Shares outstanding 5 | 188.53M |
| Implied shares outstanding 6 | 188.53M |
| Float 8 | 139.57M |
| % held by insiders 1 | 4.13% |
| % held by institutions 1 | 44.01% |
| Shares short (15 Apr 2024) 4 | 10.58M |
| Short ratio (15 Apr 2024) 4 | 9.33 |
| Short % of float (15 Apr 2024) 4 | 7.56% |
| Short % of shares outstanding (15 Apr 2024) 4 | 5.61% |
| Shares short (prior month 15 Mar 2024) 4 | 9.98M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 3:1 |
| Last split date 3 | 31 Oct 1997 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | -240.20% |
| Operating margin (ttm) | -135.63% |
Management effectiveness
| Return on assets (ttm) | -11.80% |
| Return on equity (ttm) | -32.07% |
Income statement
| Revenue (ttm) | 8.95M |
| Revenue per share (ttm) | 0.05 |
| Quarterly revenue growth (yoy) | 9.00% |
| Gross profit (ttm) | N/A |
| EBITDA | -20.51M |
| Net income avi to common (ttm) | -21.49M |
| Diluted EPS (ttm) | -0.1200 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 35.49M |
| Total cash per share (mrq) | 0.19 |
| Total debt (mrq) | 2.95M |
| Total debt/equity (mrq) | 4.76% |
| Current ratio (mrq) | 2.14 |
| Book value per share (mrq) | 0.36 |
Cash flow statement
| Operating cash flow (ttm) | -28.57M |
| Levered free cash flow (ttm) | -10.37M |
© 2024 Yahoo. All rights reserved.